news
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
List view / Grid view
Antibodies
news
Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials
Researchers have developed a monoclonal antibody called AR-711 that is highly neutralising against COVID-19 in an inhaled formulation.
news
NIAID trial to identify potential COVID-19 treatments for further development
The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
news
US FDA approves the first Ebola virus treatment – Inmazeb
The US Food and Drug Administration (FDA) has approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus infection in adults and children.
news
Celltrion COVID-19 antibody treatment to enter Phase III trial
Celltrion Group's CT-P59 antibody will be tested as a COVID-19 prophylactic in a Phase III clinical trial.
news
US enters agreement for experimental prophylactic COVID-19 antibody cocktail
The US government will develop and manufacture AstraZeneca’s investigational monoclonal antibody cocktail, AZD7442, a potential prophylactic treatment for COVID-19.
news
Eli Lilly provides update on COVID-19 antibody programmes
Eli Lilly has given an update on its neutralising antibody programmes, including its combination therapy in patients with COVID-19.
news
Phase III trial to study REGN-COV2, potential COVID-19 antibody treatment
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
news
Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers
A first-in-human Phase I clinical trial of potential COVID-19 antibody CT-P59 has shown the treatment is well tolerated in healthy subjects.
news
Russia’s Sputnik V COVID-19 vaccine safely elicits an antibody response, reports paper
Preliminary data from Phase I/II trails evaluating the vaccine reveal 100 percent of participants had a humoral and cellular response, with no serious adverse events reported.
news
MHRA issues positive opinion to avelumab for Early Access to Medicines Scheme
The UK MHRA has given a positive scientific opinion for Merck and Pfizer's avelumab on the Early Access to Medicines Scheme (EAMS).
article
Overview of workflows and data approaches in bioproduction – an industry perspective
Downstream processing is an integral part of the production process of biopharmaceuticals and contributes quite significantly to the overall productivity and product quality, as well as to processing costs. Melanie Diefenbacher of Genedata provides a comprehensive overview of downstream processes, highlighting several challenges and the importance of investing into automation…
news
AstraZeneca doses first patients in COVID-19 therapy trial
The Phase I trial will assess the safety and pharmacokinetics of the AZD7442 monoclonal antibody combination in 48 healthy participants.
news
Two Phase III trials in US to evaluate efficacy of mAbs against COVID-19
Two randomised Phase III clinical trials to test mAbs against COVID-19 are now enrolling healthy adults in the US, the NIH has announced.
news
Interleukin-6 inhibitors improve outcomes for COVID-19 patients in study
Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.
